Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus.
Non-insulin-dependent, or type II, diabetes mellitus is characterized by a progressive impairment of glucose-induced insulin secretion by pancreatic beta cells and by a relative decreased sensitivity of target tissues to the action of this hormone. About one third of type II diabetic patients are treated with oral hypoglycemic agents to stimulate insulin secretion. These drugs however risk inducing hypoglycemia and, over time, lose their efficacy. An alternative treatment is the use of glucagon-like peptide-1 (GLP-1), a gut peptidic hormone with a strong insulinotropic activity. Its activity depends of the presence of normal blood glucose concentrations and therefore does not risk inducing hypoglycemia. GLP-1 can correct hyperglycemia in diabetic patients, even in those no longer responding to hypoglycemic agents. Because it is a peptide, GLP-1 must be administered by injection; this may prevent its wide therapeutic use. Here we propose to use cell lines genetically engineered to secrete a mutant form of GLP-1 which has a longer half-life in vivo but which is as potent as the wild-type peptide. The genetically engineered cells are then encapsulated in semi-permeable hollow fibers for implantation in diabetic hosts for constant, long-term, in situ delivery of the peptide. This approach may be a novel therapy for type II diabetes.
Institute of Pharmacology and Toxicology, University of Lausanne, Switzerland.
R
R
Burcelin
E
E
Rolland
W
W
Dolci
S
S
Germain
V
V
Carrel
B
B
Thorens
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000628:therapy*; D005818:Genetic Engineering; D005934:Glucagon / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006801:Humans; D008567:Membranes, Artificial; D051379:Mice; D009154:Mutation; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism* / Q000627:therapeutic use
D008567:Membranes, Artificial; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon